



BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update

August 2, 2018

Conference call scheduled on August 8, 2018 at 4:30 PM ET

NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018. The Company will hold a conference call at 4:30 PM Eastern Time on Wednesday, August 8, 2018 to discuss the financial results and provide a business update.

CONFERENCE CALL & WEBCAST-

Wednesday, August 8, 2018, 4:30 p.m. Eastern Time

Domestic: 800-347-6311

International: 323-794-2094

Conference ID: 8850726

Webcast: <http://public.viavid.com/index.php?id=130885>

Replay – Available through September 8, 2018

Domestic: 844-512-2921

International: 412-317-6671

Conference ID: 8850726

About BioXcel Therapeutics, Inc. (BTI):

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxccltherapeutics.com.

Contact Information:

The Ruth Group for BTI:

Lee Roth / Janhavi Mohite

646-536-7012 / 7026

lroth@theruthgroup.com / jmohite@theruthgroup.com

Source: BioXcel Therapeutics, Inc.